Overview Diagnostics The latest articles, press releases and dossiers on diagnostics in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/diagnostics
BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016 DiagNeeds: translating clinical requirements into new products (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…https://www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
Press release - 24/10/2011 Curetis AG Opens Unyvero™ Cartridge Production Facility Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the opening of its state-of-the-art production facility for disposable Unyvero™ cartridges in Bodelshausen (near Tuebingen, Germany).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-opens-unyvero-cartridge-production-facility
Press release - 08/01/2009 ILM – Molecular cytogenetic diagnostics The ILM used multicolour fluorescence in-situ hybridisation for the detection of chromosomal changes in the vein tissue of patients suffering from recurrent varicosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-molecular-cytogenetic-diagnostics
Press release - 07/12/2009 Curetis AG - € 18.5 million Series A Financing Round closed A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-18-5-million-series-a-financing-round-closed
Article - 04/04/2011 Technical innovations for better diagnostics The quantitative detection of DNA single-strand breaks is of great importance for many areas of biomedical research and diagnostics. The Fluorescence-detected Alkaline DNA Unwinding FADU assay assists in the investigation of mechanisms of DNA damage and repair following DNA strand breaks upon exposure to chemicals. Prof. Alexander Bürkle and his team at the University of Konstanz have automated and optimised the original FADU assay which was…https://www.gesundheitsindustrie-bw.de/en/article/news/technical-innovations-for-better-diagnostics
Press release - 03/11/2011 Curetis AG attracts Forbion and Roche as new investors Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the expansion of its Series A financing round by € 9.6 million. The additional funds increase the round to a total of € 34.1 million and the total capital raised to date to € 36.6 million. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-attracts-forbion-and-roche-as-new-investors
Company profile: medicalvalues GmbH - 05/05/2022 medicalvalues – best possible diagnostics thanks to AI The Karlsruhe-based start-up medicalvalues GmbH wants to use its platform to bring together different clinical data sets and thus enable comprehensive medical diagnostics. Artificial intelligence featuring innovative diagnostic algorithms is used to evaluate the data and generate new insights for laboratories and hospitals.https://www.gesundheitsindustrie-bw.de/en/article/news/medicalvalues-best-possible-diagnostics-thanks-ai
Press release - 04/02/2020 CeGaT Brings New Dimension to Exome Diagnostics CeGaT aims to solve all genetically-caused cases of disease to help physicians state a diagnosis. To pursue this goal, CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool: CeGaT Exome Xtra is the most powerful genetic diagnostic option for patients with complex, unspecific, and rare diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-ermoeglicht-neue-dimension-der-exom-diagnostik
Press release - 04/11/2010 LifeCodexx Appoints Head of Commercial Operations Dr. Martin Burow, a proven expert in the field of prenatal diagnostics, has joined the LifeCodexx team as Head of Commercial Operations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lifecodexx-appoints-head-of-commercial-operations
Article - 13/01/2014 DIARECT AG – development and production of immunodiagnostics components Founded by Dr. Heinz Haubruck and Prof. Dr. Bodo Liedvogel in 1998, the biotechnology company DIARECT AG (DIAgnostic by RECombinant Technology) from Freiburg sells tried and tested and new products. The company produces proteins, nucleoproteins and assay components for the diagnostics sector. These products enable the reliable identification of autoimmune disorders and infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/diarect-ag-development-and-production-of-immunodiagnostics-components
Article - 12/03/2012 Q-bios provides client-specific biotechnology services Q-bios GmbH, a spin-off from the Mannheim University of Applied Sciences, is a biotechnology company that provides services related to the production and purification of diagnostic and therapeutic proteins as well as the development and amplification of suitable cell lines. The company offers its services, which are based on state-of-the-art technologies, to clients from the biotechnology, diagnostic and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/q-bios-provides-client-specific-biotechnology-services
Dossier - 08/09/2022 Imaging methods in medical diagnostics Many different imaging methods are available these days and are used in almost all medical disciplines to visualise disease-related changes. Depending on the problem and the clinical picture, very different structural and functional parameters can be visually recorded for diagnosis and used for therapy.https://www.gesundheitsindustrie-bw.de/en/article/dossier/imaging-methods-medical-diagnostics
Dossier - 30/08/2010 Disease prevention through better diagnostics “Classical treatment approaches are not the only way to ensure good health, rehabilitation and care. In fact, it is envisaged that more effective prevention will contribute to halting the development of diseases and maintaining good health. Prevention is designed to prevent health risks and diseases, make them less likely and delay their onset.” (Declaration of the German government; Official Records of Parliament 17/845, 26th February 2010) https://www.gesundheitsindustrie-bw.de/en/article/dossier/disease-prevention-through-better-diagnostics
Press release - 04/02/2010 QIAGEN acquires ESE GmbH QIAGEN N.V. has announced its acquisition of ESE GmbH a privately owned developer and manufacturer of UV and fluorescence optical measurement devices. ESE GmbH is based in Stockach Germany. The cash transaction is valued at up to US19 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/qiagen-acquires-ese-gmbh
Article - 30/08/2010 Genetic testing for the prevention of diseases? Genetic testing is beginning to play an important role in personalised medicine and is indispensable for the diagnosis and therapy of many diseases. However, the preventive and diagnostic power of many genetic tests is still inferior to traditional diagnostic tests. In addition, commercial genetic tests do not always live up to the claims made about them. https://www.gesundheitsindustrie-bw.de/en/article/news/genetic-testing-for-the-prevention-of-diseases
Press release - 23/05/2011 GATC Biotech and LifeCodexx develop a diagnostic test for early detection of preeclampsia Preeclampsia is a hypertensive disorder of the mother during pregnancy. It is among the leading causes of death of mother and unborn child and occurs in approximately two to five percent of all pregnancies in Germany. Early detection is critical and improves the prognosis for the further course of the pregnancy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-biotech-and-lifecodexx-develop-a-diagnostic-test-for-early-detection-of-preeclampsia
Biotech start-up from Frickenhausen develops chewing gum as test system for bacteria - 19/12/2019 A medical connoisseur – the tongue as a sensor for infections The start-up 3a-diagnostics GmbH from Frickenhausen is developing a gum that can be used both in doctors’ surgeries and at home as a quick and easy diagnostic aid. The sensor in this case is the human tongue. If bacteria are present – due to an inflammation of the teeth or tonsils, for instance – chewing produces a bitter taste and the doctor can quickly initiate the appropriate treatment. https://www.gesundheitsindustrie-bw.de/en/article/press-release/medizinischer-feinschmecker-die-zunge-als-sensor-fuer-infektionen
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Article - 20/10/2014 QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-pocket-sized-laboratories-for-the-efficient-identification-of-pathogens
Press release - 04/07/2008 Bracco Imaging: specialist in diagnostic imaging In future small bubbles will allow the identification of pathological alterations at a very early stage. Molecular imaging methods developed by Bracco Imaging S.p.A. use a new ultrasound contrast agent. The German subsidiary of the company Bracco Imaging Deutschland GmbH based in Constance develops and sells contrast agents.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bracco-imaging-specialist-in-diagnostic-imaging
Press release - 25/11/2010 BD Diagnostics and Lonza Collaborate BD Diagnostics, a segment of BD (Becton, Dickinson and Company), and Lonza Group Ltd announced today that they have entered into an exclusive licensing and collaboration agreement for Lonza to commercialize its microCompass™ molecular assays on the BD MAX™ System.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bd-diagnostics-and-lonza-collaborate
Article - 10/05/2010 CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing new challenges due to the enormous technological progress made in this field. The market requires technically feasible solutions reliable and rapid sequence analyses in which entire genomes can be analysed within a couple of days or weeks. This can only be achieved with state-of-the-art high-throughput technologies. Tübingen-based CeGaT GmbH has been offering DNA and RNA sequencing using state-of-the-art…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-dna-and-rna-sequencing-specialist
Press release - 26/04/2008 Curetis AG - Compact weapon against tuberculosis In conjunction with reference laboratories of the World Health Organization WHO medtech company Curetis AG is developing new technologies and products that identify the pathogens of infectious diseases such as tuberculosis and their resistance. The solutions are impressive. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-compact-weapon-against-tuberculosis